Vermillion, Inc., together with its subsidiaries, engages in the discovery, development, and commercialization of diagnostic tests that help physicians diagnose, treat, and enhance outcomes for patients. The company develops diagnostic tests in the fields of oncology, cardiology, and womens health. Its lead product is OVA1, an ovarian cancer blood test for pre-surgical identification of women who are at high risk of having a malignant ovarian tumor. The company is also involved in developing various programs in other clinical aspects of ovarian cancer, as well as in peripheral arterial disease. Vermillion, Inc. has strategic alliance agreement with Quest Diagnostics Incorporated to develop and commercialize diagnostic tests. It serves clinical reference laboratories, hospital laboratories, and physician offices. The company was formerly known as Ciphergen Biosystems, Inc. and changed its name to Vermillion, Inc. in August 2007. Vermillion, Inc. was founded in 1993 and is headquartered in Austin, Texas.